Egypt Infectious Disease Therapeutics Market Report 2022 to 2030

Egypt Infectious Disease Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Egypt infectious disease therapeutics market will reach a value of $528.93 Mn from $335.64 Mn in 2022, growing at a CAGR of 5.9% during 2022-2030. The Infectious Disease Therapeutics in Egypt is dominated by a few domestic pharmaceutical companies such as EIPICO, Pharco Pharmaceuticals and Memphis Pharmaceutical. The Infectious Disease Therapeutics market in Egypt is segmented into different therapeutic areas and different diseases type. The major factors affecting the Egypt infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various of areas of Egypt.

ID: IN10EGPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Dr. Vishwa Modhia

Buy Now

Egypt Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Egypt infectious disease therapeutics market will reach a value of $528.93 Mn from $335.64 Mn in 2022, growing at a CAGR of 5.9% during 2022-2030.

Egypt is a lower middle-income, developing country in North Africa that borders the Red Sea and the Mediterranean Sea. Egypt is intermediate prone to infectious diseases, according to the World Factbook. Food or waterborne diseases include bacterial diarrhoea, hepatitis A, and typhoid fever. Schistosomiasis is a water contact disorder in Egypt.

Egypt is also involved in vaccine development, with the National Organization for Research and Control of Biologicals (NORCB) in charge of vaccine production in the country. The NORCB manufactures vaccinations for a variety of diseases, including hepatitis B, tetanus, and diphtheria. Egypt's government spends 4.4% of its GDP on healthcare.

Egypt Infectious Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Egypt has a high prevalence of infectious diseases, the most prevalent of which are hepatitis C, tuberculosis, and diarrheal disorders. The development and availability of infectious illness treatments are critical for preventing and treating these ailments. Egypt has seen major advances in infectious illness therapies in recent years. Egypt, for example, has achieved great progress in the treatment of hepatitis C, thanks to the introduction of new direct-acting antiviral medicines with high cure rates and lower costs than earlier therapies. Egypt has also been attempting to treat tuberculosis by boosting access to diagnostic equipment and developing new medications. Egypt has a favourable geopolitical status as a result of the Suez Canal. These aspects could boost Egypt's infectious disease therapeutics market.

Market Restraints

Developing new pharmaceuticals and treatments necessitates adherence to regulatory rules established by agencies such as the Egyptian Drug Authority (EDA). These requirements can be complicated and time-consuming, resulting in delays and higher expenses. Antibiotic overuse has resulted in the creation of drug-resistant bacteria, making it more difficult to treat infectious infections. This resistance can restrict the effectiveness of existing medications and increase the need for new treatments. These factors may deter new entrants into the Egypt infectious disease therapeutics market.

Competitive Landscape

Key Players

Pharco Pharmaceuticals - Pharco Pharmaceuticals is an Egyptian pharmaceutical company that develops and manufactures a range of therapeutics, including antibiotics and antivirals
EIPICO - EIPICO is an Egyptian pharmaceutical company that develops and manufactures a range of drugs, including antibiotics, antivirals, and antifungals
Memphis Pharmaceutical and Chemical Industries - Memphis Pharmaceutical and Chemical Industries is an Egyptian pharmaceutical company that develops and manufactures a range of drugs, including antibiotics and antivirals
Amoun Pharmaceutical Company - Amoun Pharmaceutical Company is an Egyptian pharmaceutical company that has been involved in the development of treatments for infectious diseases such as hepatitis B and C

Recent Notable Updates

June 2022: EIPICO Pharmaceutical Enterprise, ACDIMA's largest company, has struck a collaboration deal with Greenmea & E L Square. The contract signing EIPICO aims with this agreement to apply the technologies of the Fourth Industrial Revolution and the required phases for a comprehensive digital transformation of the elements of production lines, supply chains, and warehouses by leveraging the E L Square and Greenmea alliance's global technical expertise in this field.

Healthcare Policies and Reimbursement Scenarios

The Egyptian Drug Authority is in charge of the regulation of infectious disease medications in Egypt (EDA). Following the approval of a product, the EDA continues to monitor its safety and quality through post-marketing monitoring. In terms of reimbursement, Egypt has a mixed healthcare system that includes both public and private providers. Through the Ministry of Health and Populace (MoHP) and the Health Insurance Organization, the government offers subsidised healthcare services to the population, including treatments for infectious diseases (HIO).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

Vaccines
Drugs

By Applications (Revenue, USD Billion):

HIV/AIDS
Influenza
Hepatitis
Malaria
Tuberculosis
Others

By Disease Type (Revenue, USD Billion):

Viral Diseases
Bacterial Diseases
Fungal Diseases
Parasitic Diseases
Others

By Target Organism (Revenue, USD Billion):

Antibiotics
Antivirals
Antifungals
Anti-Parasitic
Others

By End User (Revenue, USD Billion):

Hospitals and Clinics
Ambulatory Care Centers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

By 2030, it is anticipated that the Egypt infectious disease therapeutics market will reach a value of $528.93 Mn from $335.64 Mn in 2022, growing at a CAGR of 5.9% during 2022-2030.

In Egypt, the regulation of infectious disease therapeutics is overseen by the Egyptian Drug Authority (EDA). The government provides subsidized healthcare services to the population, including treatments for infectious diseases, through the Ministry of Health and Population (MoHP) and the Health Insurance Organization (HIO).

The Infectious Disease Therapeutics in Egypt is dominated by a few domestic pharmaceutical companies such as EIPICO, Pharco Pharmaceuticals and Memphis Pharmaceutical.